Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 14;47(3):62.
doi: 10.1007/s10529-025-03604-5.

Discovery of novel compound IGYZT01060 for inhibition of IRAK-4 enzyme for the treatment of sepsis

Deepali Shrivastava  1 , Lavleen K Gupta  2 , Adinarayana Reddy Yerrapureddy  2 , Sampath Kumar Nune Satya  3
Affiliations

Discovery of novel compound IGYZT01060 for inhibition of IRAK-4 enzyme for the treatment of sepsis

Deepali Shrivastava et al. Biotechnol Lett. .

Abstract

Purpose: This study aimed at the discovery of a novel chemical entity, IGYZT01060 for inhibiting IRAK-4 (Interleukin-1 receptor-associated kinase 4) and testing its ability to inhibit the IRAK-4 enzyme, that is crucial in the context of sepsis due to its central role in the innate immune response, particularly in mediating inflammatory signals from Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs).

Methods: This study explores the synthesis and characterization of a novel compound, IGYZT01060, designed to inhibit IRAK-4. The inhibitory analysis was carried out in silico, in vitro and in vivo. Molecular docking was done using AutoDock software. The in vitro assays were carried out in LPS induced THP-1 cells. ADME assays were carried out for understanding the drug delivery and distribution pattern. Lastly, in vivo mice sepsis model using intraperitoneally administered LPS and orally administered compound IGYZT01060 was studied estimate the efficacy of compound IGYZT01060.

Results: In silico docking analyses demonstrated a high affinity of IGYZT01060 for IRAK-4, with target prediction indicating a preference for kinase enzymes. The NMR spectroscopy confirmed the successful synthesis and purity of the compound. In vitro studies revealed that IGYZT01060 effectively inhibits IRAK-4 with an IC50 of less than 100 nM. Pharmacokinetic evaluations indicated a favorable clearance rate and high bioavailability, essential for the therapeutic efficacy of any drug. Furthermore, the mice sepsis model results indicated a significant inhibition of IRAK-4, almost as good as the corticosteroid dexamethasone.

Conclusion: The promising IRAK-4 inhibition demonstrated by our compound IGYZT01060, along with its favourable pharmacokinetic profile and significant efficacy in a mice sepsis model, highlights its potential as a powerful therapeutic option for treating inflammatory conditions.

Keywords: IRAK-4 inhibition; NF-κB; Sepsis; Septic shock.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose.

Similar articles

See all similar articles

References

    1. AbdAllah NB, Toraih EA, Al Ageeli E et al (2021) MYD88, NFKB1, and IL6 transcripts overexpression are associated with poor outcomes and short survival in neonatal sepsis. Sci Rep 11(1):13374. https://doi.org/10.1038/s41598-021-92669-0 - DOI - PubMed - PMC
    1. Ackerman L, Acloque G, Bacchelli S et al (2023) IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nat Med 29(12):3127–3136. https://doi.org/10.1038/s41591-023-02635-7 - DOI - PubMed - PMC
    1. Alghamdi SS, Suliman RS, Almutairi K et al (2021) Imidazole as a promising medicinal scaffold: current status and future direction. Drug Des Dev Ther 15:3289–3312. https://doi.org/10.2147/DDDT.S307113 - DOI
    1. Almazroo OA, Miah MK, Venkataramanan R (2017) Drug metabolism in the liver. Clin Liver Dis 21(1):1–20. https://doi.org/10.1016/j.cld.2016.08.001 - DOI - PubMed
    1. Amr AGE, Abdulla MM (2006) Anti-inflammatory profile of some synthesized heterocyclic pyridone and pyridine derivatives fused with steroidal structure. Bioorg Med Chem 14(13):4341–4352. https://doi.org/10.1016/j.bmc.2006.02.045 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources